BCYC News and Press, Bicycle Therapeutics plc From 04/08/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Bicycle Therapeutics (NASDAQ:BCYC) is trading sharply higher on Friday after the clinical-stage biotech announced promising interim Phase I results for its cancer candidate BT8009 in a group of patients with solid tumors. The data were shared at the ongoing 2022 American Association for Cance...

- Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced updated preclinical results providing further evidence for Bicycles ...

Bicycle Therapeutics plc (NASDAQ:BCYC) traded at a new 52-week high today of $62.19. This new high was reached on above average trading volume as 3.5 million shares traded hands, while the average 30-day volume is approximately 261,000 shares. Bicycle Therapeutics plc share prices have m...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will participate in a fireside chat at the 21 st Ann...

Shares of Bicycle Therapeutics have risen by 68% over the past 12 months and 252% over the past 3 years. I provide a recap of the bullish thesis and my prior notes on this differentiated platform technology play. Bicycle Toxin Conjugates (BTCs) appear to have several advantages ov...

- Four Additional Abstracts Selected as Poster Presentations at the Meeting - Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of thera...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will participate in a fireside chat at the Oppenheimer 3...

Bicycle Therapeutics press release (NASDAQ:BCYC): Q4 GAAP EPS of -$0.63 beats by $0.01. Revenue of $3.77M (-2.1% Y/Y) misses by $1.11M. For further details see: Bicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11M